-$0.58 EPS Expected for Redhill Biopharma Ltd. (RDHL) This Quarter

Brokerages expect Redhill Biopharma Ltd. (NASDAQ:RDHL) to announce earnings of ($0.58) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Redhill Biopharma’s earnings, with the highest EPS estimate coming in at ($0.51) and the lowest estimate coming in at ($0.62). Redhill Biopharma reported earnings of ($0.60) per share in the same quarter last year, which would indicate a positive year over year growth rate of 3.3%. The business is scheduled to issue its next quarterly earnings report on Tuesday, July 25th.

On average, analysts expect that Redhill Biopharma will report full-year earnings of ($2.23) per share for the current fiscal year, with EPS estimates ranging from ($2.35) to ($2.04). For the next year, analysts anticipate that the business will report earnings of ($2.23) per share, with EPS estimates ranging from ($2.40) to ($2.05). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that follow Redhill Biopharma.

Redhill Biopharma (NASDAQ:RDHL) last issued its earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.14.

Several research analysts recently issued reports on RDHL shares. FBR & Co reiterated a “buy” rating on shares of Redhill Biopharma in a research note on Friday. HC Wainwright set a $33.00 price target on shares of Redhill Biopharma and gave the stock a “buy” rating in a research note on Thursday. Finally, Roth Capital set a $26.00 price target on shares of Redhill Biopharma and gave the stock a “buy” rating in a research note on Thursday, May 4th.

COPYRIGHT VIOLATION NOTICE: This news story was posted by sleekmoney and is owned by of sleekmoney. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://sleekmoney.com/0-58-eps-expected-for-redhill-biopharma-ltd-rdhl-this-quarter/1916247.html.

Hedge funds have recently added to or reduced their stakes in the stock. Family Management Corp purchased a new stake in Redhill Biopharma during the first quarter worth $163,000. Jane Street Group LLC purchased a new stake in Redhill Biopharma during the first quarter worth $276,000. Oppenheimer & Co. Inc. raised its stake in Redhill Biopharma by 36.5% in the first quarter. Oppenheimer & Co. Inc. now owns 23,069 shares of the biotechnology company’s stock worth $221,000 after buying an additional 6,172 shares in the last quarter. Renaissance Technologies LLC raised its stake in Redhill Biopharma by 144.1% in the first quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock worth $595,000 after buying an additional 36,600 shares in the last quarter. Finally, Penserra Capital Management LLC raised its stake in Redhill Biopharma by 75.0% in the first quarter. Penserra Capital Management LLC now owns 17,843 shares of the biotechnology company’s stock worth $171,000 after buying an additional 7,647 shares in the last quarter. Institutional investors and hedge funds own 12.31% of the company’s stock.

Shares of Redhill Biopharma (NASDAQ:RDHL) traded down 5.91% during mid-day trading on Friday, reaching $8.60. 170,786 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $9.68 and a 200 day moving average price of $10.06. Redhill Biopharma has a 52-week low of $8.40 and a 52-week high of $16.54. The firm’s market cap is $146.26 million.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a biopharmaceutical company. The Company is focused on the development and commercialization of clinical-stage, orally-administered, small molecule drugs for the treatment of gastrointestinal (GI) and inflammatory diseases and cancer. Its seven clinical-stage therapeutic candidates include RHB-105, RHB-104, BEKINDA, RHB-106, YELIVA, MESUPRON and RIZAPORT and related research and development programs.

Get a free copy of the Zacks research report on Redhill Biopharma (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/0-58-eps-expected-for-redhill-biopharma-ltd-rdhl-this-quarter/1916247.html

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *